Growth Metrics

Edwards Lifesciences (EW) Change in Receivables (2016 - 2026)

Edwards Lifesciences has reported Change in Receivables over the past 17 years, most recently at -$32.4 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 69.41% year-over-year to -$32.4 million; the TTM value through Dec 2025 reached $23.0 million, up 118.98%, while the annual FY2025 figure was $23.0 million, 118.98% up from the prior year.
  • Change in Receivables for Q4 2025 was -$32.4 million at Edwards Lifesciences, down from -$13.2 million in the prior quarter.
  • Over five years, Change in Receivables peaked at $89.5 million in Q1 2021 and troughed at -$105.9 million in Q4 2024.
  • A 5-year average of $10.9 million and a median of $11.8 million in 2022 define the central range for Change in Receivables.
  • Biggest five-year swings in Change in Receivables: soared 2030.95% in 2021 and later crashed 3538.46% in 2024.
  • Year by year, Change in Receivables stood at -$6.8 million in 2021, then skyrocketed by 116.18% to $1.1 million in 2022, then soared by 1554.55% to $18.2 million in 2023, then tumbled by 681.87% to -$105.9 million in 2024, then surged by 69.41% to -$32.4 million in 2025.
  • Business Quant data shows Change in Receivables for EW at -$32.4 million in Q4 2025, -$13.2 million in Q3 2025, and $24.9 million in Q2 2025.